This randomized controlled trial evaluated 68 women undergoing elective cesarean section. The study aimed to assess the impact of perioperative pharmacological intervention on postpartum recovery metrics.
The intervention group received an intravenous bolus infusion of 0.5 μg/kg dexmedetomidine within 15 min following fetal delivery. The comparator group received an equal volume of normal saline.
Primary analysis showed sleep quality scores were significantly higher in Group D than in Group C with a p < 0.05. Activity-related pain scores were also reduced in Group D. Follow-up assessments occurred on the 1st, 2nd, 3rd day and 6th week postoperatively for sleep quality. Additional outcomes included STAI scores, resting pain scores, 24 h consumption of patient-controlled PCEA, incidence of intraoperative shivering, EPDS scores, and NBNA scores. STAI scores were measured on the 1st, 2nd and 3rd day postoperatively. Pain and shivering were assessed 24 h postoperatively. EPDS scores were evaluated at the 6th week postoperatively. NBNA scores were recorded within 24 h/48 h after surgery.
Safety data including adverse events, serious adverse events, and discontinuations were not reported. Tolerability information was also not reported. The study did not list specific limitations or funding sources.
Clinicians should note that while sleep quality improved, the absence of safety reporting limits comprehensive risk assessment. Further investigation is needed to confirm long-term outcomes and safety profiles in this population.
View Original Abstract ↓
Perinatal sleep disturbance is highly prevalent among women undergoing elective cesarean section. Dexmedetomidine has been proven effective in improving sleep quality in patients undergoing general surgery, and this study aimed to investigate its potential efficacy in improving postoperative sleep quality in the elective cesarean section population.
A total of 68 parturients scheduled for elective cesarean section were randomly allocated to the dexmedetomidine group (Group D) and the control group (Group C). Following fetal delivery, Group D received an intravenous bolus infusion of 0.5 μg/kg dexmedetomidine within 15 min, while Group C was administered an equal volume of normal saline as a control. Outcome measures included sleep quality scores at 1st, 2nd, 3rd day and 6th week postoperatively, STAI score at 1st, 2nd and 3rd day postoperatively, resting and activity-related pain scores at 24 h postoperatively, 24-h consumption of patient-controlled PCEA, the incidence of intraoperative shivering, EPDS scores at 6th week postoperatively and NBNA scores within 24 h/48 h after surgery. All outcomes were systematically recorded and compared between the two groups.
Group D had significantly higher sleep quality scores than Group C at the first postoperative night and 6th week postoperatively (p
For parturients undergoing elective cesarean section, intraoperative intravenous bolus infusion of dexmedetomidine exerts a positive effect on improving sleep quality at the first postoperative night and 6th week postoperatively, as well as reducing activity-related pain scores at 24 h postoperatively.
Chinese Clinical Trial Registry (ChiCTR2500106212) https://www.chictr.org.cn/showprojEN.html?proj=280761.